ID: ALA281024

Max Phase: Preclinical

Molecular Formula: C18H21N8O7P

Molecular Weight: 492.39

Molecule Type: Small molecule

Representations

Canonical SMILES:  Nc1nc(N)c2nc(CNc3ccc(C(=O)NC(CCOP(=O)(O)O)C(=O)O)cc3)cnc2n1

Standard InChI:  InChI=1S/C18H21N8O7P/c19-14-13-15(26-18(20)25-14)22-8-11(23-13)7-21-10-3-1-9(2-4-10)16(27)24-12(17(28)29)5-6-33-34(30,31)32/h1-4,8,12,21H,5-7H2,(H,24,27)(H,28,29)(H2,30,31,32)(H4,19,20,22,25,26)

Standard InChI Key:  OFDRKIQYYPSMTJ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 492.39

Molecular Weight (Monoisotopic): 492.1271

AlogP: -0.12

#Rotatable Bonds: 10

Polar Surface Area: 248.79

Molecular Species: ACID

HBA: 11

HBD: 7

#RO5 Violations: 2

HBA (Lipinski): 15

HBD (Lipinski): 9

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 1.66

CX Basic pKa: 6.83

CX LogP: -2.21

CX LogD: -7.80

Aromatic Rings: 3

Heavy Atoms: 34

QED Weighted: 0.18

Np Likeness Score: -0.29

References

1. Rosowsky A, Bader H, Kohler W, Freisheim JH, Moran RG..  (1988)  Methotrexate analogues. 34. Replacement of the glutamate moiety in methotrexate and aminopterin by long-chain 2-aminoalkanedioic acids.,  31  (7): [PMID:2898531] [10.1021/jm00402a014]

Source

Source(1):

• Scientific Literature